30
Participants
Start Date
April 28, 2023
Primary Completion Date
January 31, 2024
Study Completion Date
January 31, 2024
Remimazolam
Remimazolam is a recently approved medication used for the induction of general anesthesia and maintenance of sedation. There have been no prior studies using remimazolam for the induction of anesthesia in ECT, and this research aims to investigate the feasibility of using remimazolam as an induction agent for ECT.
Etomidate
Etomidate is widely used in ECT due to its rapid onset, stable hemodynamic profile, and quick recovery. In this study, remimazolam will be used as the experimental group, while etomidate will serve as the control group.
Dankook University Hospital, Cheonan
Yeongseok Yun
OTHER